脑梗死早期应用依达拉奉治疗的临床疗效观察
2020-12-23吕焱清
吕焱清

【摘要】 目的 探讨依达拉奉对脑梗死早期的应用效果。方法 34例早期急性脑梗死患者, 以抽签法随机分为对照组(16例)和观察组(18例)。对照组给予丹参注射液治疗, 观察组在对照组基础上给予依达拉奉治疗。对比两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分和日常生活活动能力量表(ADL)评分、临床治疗效果。结果 治疗后, 观察组的NIHSS评分(7.62±3.28)分低于对照组的(14.32±4.11)分, ADL评分(90.31±2.34)分高于对照组的(70.16±3.64)分, 差异有统计学意义(P<0.05)。观察组临床治疗总有效率88.89%高于对照组的56.25%, 差异有统计学意义(P<0.05)。结论 对早期急性脑梗死患者应用依达拉奉治疗可改善其神经功能缺损症状, 提高其日常生活活动能力, 值得大力推广。
【关键词】 急性脑梗死;依达拉奉;神经功能缺损;日常生活活动能力
DOI:10.14163/j.cnki.11-5547/r.2020.31.037
Observation of the clinical efficacy of edaravone in the early treatment of cerebral infarction LYU Yan-qing. Department of Internal Medicine-Neurology, Dongguan Fenggang Hospital, Dongguan 523695, China
【Abstract】 Objective To discuss the practical effect of edaravone in the early treatment of cerebral infarction. Methods A total of 34 patients with early acute cerebral infarction were divided into control group (16 cases) and observation group (18 cases) according to lottery method. The control group was treated with Danshen injection, and the observation group was treated with edaravone on the basis of the control group. The National Institutes of Health stroke scale (NIHSS) score and activities of daily living (ADL) score before and after treatment, and clinical effect were compared between the two groups. Results After treatment, NIHSS score (7.62±3.28) points of the observation group was lower than (14.32±4.11) points of the control group, and ADL score (90.31±2.34) points was higher than (70.16±3.64) points of the control group, and the difference was statistically significant (P<0.05). The total effective rate of clinical treatment 88.89% of the observation group was higher than 56.25% of the control group, and the difference was statistically significant (P<0.05). Conclusion Edaravone to patients with early acute cerebral infarction can improve their neurological deficit symptoms and improve their activities of daily living, which is worthy of vigorous promotion.
【Key words】 Acute cerebral infarction; Edaravone; Neurological deficits; Activities of daily living
脑梗死又可称为缺血性卒中, 是临床十分常见的一类神经内科疾病, 多发于老年群体, 具有较高的发病率、致残率和致亡率, 严重威胁患者的生命安全[1]。由于脑梗死急性发作时病情较为危重, 且临床有效治疗方法较少, 一旦用药不当, 将会加重其脑组织损伤程度, 甚至会造成患者死亡, 因此, 应当在疾病发展早期及时进行有效干预治疗, 且尽量选择更利于改善患者脑缺氧症状, 且毒副作用较少的药物[2]。依达拉奉作为一种强有效的神经保护剂, 经大量研究发现, 将其应用至脑梗死急性发作期患者的临床治疗中可抑制其梗死周围局部脑血流量的减少, 并可缓解其伴随的神经症状, 避免出现迟发性神经元死亡。为进一步提高脑梗死早期患者的临床治疗有效率, 本文将依达拉奉应用其中, 以观察其应用價值, 现报告如下。
1 资料与方法
1. 1 一般资料 择取2018年9月~2019年9月收治的34例早期急性脑梗死患者作为研究对象, 通过抽签的方式随机分为对照组(16例)和观察组(18例)。……
